NeOnc Technologies announced it will present data on its NEO100 and NEO212 clinical programs at the Society for Neuro-Oncology's 2026 Annual Meeting, highlighting progress in CNS cancer therapies. The data event adds visibility to the clinical development pipeline and therapeutic potential of the company's portfolio.